Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.16)
# 1,452
Out of 4,479 analysts
16
Total ratings
46.15%
Success rate
-2.31%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Maintains: In-Line | $139 → $185 | $154.20 | +19.97% | 7 | Jun 24, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $65 | $22.78 | +185.34% | 1 | Apr 3, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $594 → $436 | $435.49 | +0.12% | 2 | Dec 21, 2023 | |
| MIRM Mirum Pharmaceuticals | Reinstates: Outperform | $62 | $33.68 | +84.09% | 1 | Oct 17, 2023 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $22 | $1.14 | +1,829.82% | 1 | Oct 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $20 → $10 | $4.52 | +121.24% | 1 | May 30, 2023 | |
| ABBV AbbVie | Maintains: Outperform | $159 → $165 | $165.96 | -0.58% | 2 | Feb 9, 2023 | |
| INBX Inhibrx | Maintains: Outperform | $54 → $60 | $13.56 | +342.48% | 1 | Oct 5, 2022 |
Sarepta Therapeutics
Jun 24, 2024
Maintains: In-Line
Price Target: $139 → $185
Current: $154.20
Upside: +19.97%
Jasper Therapeutics
Apr 3, 2024
Initiates: Outperform
Price Target: $65
Current: $22.78
Upside: +185.34%
argenx SE
Dec 21, 2023
Maintains: Outperform
Price Target: $594 → $436
Current: $435.49
Upside: +0.12%
Mirum Pharmaceuticals
Oct 17, 2023
Reinstates: Outperform
Price Target: $62
Current: $33.68
Upside: +84.09%
Aclaris Therapeutics
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.14
Upside: +1,829.82%
C4 Therapeutics
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $4.52
Upside: +121.24%
AbbVie
Feb 9, 2023
Maintains: Outperform
Price Target: $159 → $165
Current: $165.96
Upside: -0.58%
Inhibrx
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $13.56
Upside: +342.48%